A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Stopped early · Phase 1

Conditions studied: Cystic Fibrosis, Chronic Obstructive Pulmonary Disease

In brief

This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.

Key facts

Study ID: NCT01793649
Run by: Gilead Sciences
People needed: 7
Starts: 2012-10-01
Expected to finish: 2013-06-01
Last updated by the study team: 2014-03-20

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Body mass index (BMI) from ≥ 19 to ≤ 30 kg/m2
Normal ECG, with no history or evidence of myocardial infarction, QT prolongation, or ventricular arrhythmias
Normal (or abnormal but not clinically significant) blood pressure (BP) and heart rate(HR)
History of lifetime smoking < 5 pack-years (ie, 1 pack per day x 1 year = 1 pack-year)and non-smokers of at least 60 days duration prior to Screening
Negative screening tests for drugs of abuse (including alcohol)
Hepatitis B (HBV) surface antigen negative
Hepatitis C (HCV) antibody negative
HIV-1, 2 antibody negative
Male subjects who are sexually active must be willing to use highly effective contraception from the Baseline Visit through completion of the study and continuing for at least 90 days from the date of the last dose of study drug
Male subjects must refrain from sperm donation from the Baseline Visit through completion of the study and continuing for at least 90 days from the date of the last dose of study drug
Females of childbearing potential must have a negative serum pregnancy test
Females of childbearing potential must agree to utilize protocol recommended highly effective contraception methods from Screening throughout the duration of study treatment and for 30 days following the last dose of study drug

You may not qualify if…

Female subjects who are pregnant or lactating
History of anaphylactic reaction to any drug
Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to the study drug dosing
Presence or history of extrinsic allergy requiring treatment; hay fever is allowed unless it is active or has required treatment within the previous 2 months
Have donated blood within 56 days of study dosing
Presence or history of any pulmonary diseases (ie, asthma, emphysema, chronic bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), bronchiectasis, interstitial lung disease)
Major surgery within 6 months of Screening
Experienced symptoms of recent acute upper or lower respiratory tract infection requiring treatment within the 2 weeks prior to Screening
Have had any radiation in the past year that would cause the subject exceed recommended limits by participating in this study protocol

Where it is running

Investigational Site — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.